Publications

210. Tao Xu T, Karschnia P, Cadilha B, Dede S, Lorenz M, Seewaldt N, Nikolaishvili E, Müller K, Blobner J, Teske J, Herold J, Rejeski K, Langer S, Obeck H, Lorenzini T, Mulazzani M, Zhang W, Ishikawa-Ankerhold H, Buchholz V, Subklewe M, Thon N, Straube A, Tonn JC, Kobold S, von Baumgarten L.
In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer.
OncoImmunology 2023; in press.
JIF²⁰²¹ 7.0

210. Giannou A, Kempski J, Shiri AM, Leucke J, Zhang T, Zhao L, Zazara D, Cortesi F, Riecken K, Amezcua Vesely MA, Low JS, Xu H, Kaffe E, Garcia-Perez L, Agalioti T, Yamada Y, Jungraithmayr W, Zigmond E, Karstens KF, Steglich B, Wagner J, Konczalla L, Carambia A, Schulze K, von Felden J, May P, Briukhovetska D, ...Suarez-Gosalvez J, Kobold S, ...Huber S.
Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22.
Immunity 2023; 125–142.
JIF²⁰²¹ 43.5
https://authors.elsevier.com/sd/article/S1074761322006501

211. Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou A, Schuebel M, Jobst J, Zhang T, Doerr J, Mearkl F, Majed L, Meuller PJ, May P, Gottschlich A, Tokarew N, Leucke J, Oener A, Schwerdtfeger M, Andreu-Sanz D, Gruenmeier R, Seifert M, Michaelides S, Hristov M, Koenig LM, Cadilha B, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell R, Cerezo-Wallis D, Tejedo C, Soengas M, Bald T, Huber S, Endres S, Kobold S.
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Immunity 2023; 143-161.e11.
JIF²⁰²¹ 43.5
https://authors.elsevier.com/sd/article/S107476132200646X

210. Blaeschke F, Ortner E, Stenger D, Mahdawi J, Apfelbeck A, Habjan N, Weißer T, Kaeuferle T, Willier S, Kobold S, Feuchtinger T.
Design and evaluation of TIM-3-CD28 checkpoint fusion proteins to improve anti-CD19 CAR T-cell function
Frontiers in Immunology 2022; 13:845499.
JIF²⁰²¹ 8.8

https://pubmed.ncbi.nlm.nih.gov/35499080/

210. Demel U,  Böger M, Yousefian S, Grunert C, Zhang L, Hotz P, Gottschlich A, Köse H, Isaakidis K, Vonficht D, Grünschläger F, Rohleder E, Wagner K, Dönig J, Igl V, Brzezicha B, Baumgartner F, Habringer S, Löber J, Chapuy J, Weidinger C, Kobold S, Haas S, Busse A, Müller S, Wirth M, Schick M, Keller U.
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
The Journal of Clinical Investigation 2022; 132:e152383.

JIF²⁰²¹ 19.5

https://pubmed.ncbi.nlm.nih.gov/35499080/

210. Lesch S, Nottebrock A, Rataj F, Heise C, Endres S, Kobold S.
PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models.
Cellular Oncology 2022; in press.
JIF²⁰²¹ 7.1

https://pubmed.ncbi.nlm.nih.gov/36409438/

209. Summer B, Lill D, Remmel K, Schraml A, Schopf C, IBanke IJ, Kuechenhoff H, Maierhofer T, Endres S, Thomas P.
An interleukin-1 polymorphism additionally intensified by atopy as prognostic factor for aseptic non-mechanical complications in metal knee and hip arthroplasty.
Frontiers in Immunology 2022; in press.
JIF²⁰²¹ 8.8

208. Seifert M, Benmebarek MR, Briukhovetska D, Märkl F, Dörr J, Cadilha B, Jobst J, Stock S, Andreu-Sanz D, Lorenzini T, Grünmeier R, Öner A, Obeck H, Majed L, Dhoqina D, Feinendegen M, Gottschlich A, Zhang J, Schindler U, Endres S, Kobold S.
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function.
British Journal of Cancer 2022; 61, eabe2550.
JIF²⁰²¹ 9.1

207. Hölting TLB, Cidre-Aranaz F, Matzek D, Popper B, Jacobi SJ, Funk CM, Geyer FH, Li J, Piseddu I, Cadilha BL, Ledderose S, Zwilling J, Ohmura S, Anz D, Künkele A, Klauschen F, Grünewald TGP, Knott MML.
Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood
sarcoma.
Molecular Cancer 2022, 21:199.
JIF²⁰²¹ 41.4
https://pubmed.ncbi.nlm.nih.gov/36229873/

207. Stazzoni S, Böhmer D, Hernichel F, Özdemir D, Pappa A, Drexler D, Bauernfried S, Witte G, Wagner M, Veth S, Hopfner KP, Hornung V, König LM, Carell T.
Novel poxin stable cGAMP-derivatives are remarkable STING agonists.
Angewandte Chemie 2022; 10:e202207175.
JIF²⁰²¹ 15.3
https://pubmed.ncbi.nlm.nih.gov/35876840/

207. Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost Ch, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein Ch, Kobold S.
Chimeric antigen receptor T cells engineered to recogniz the P329G- mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Journal for Immunotherapy of Cancer 2022; 10:e005054.
JIF²⁰²¹ 12.5
https://jitc.bmj.com/content/10/7/e005054

206. Bashiri Dezfouli A, Yazdi M, Benmebarek MR, Schwab M, Michaelides S, Miccichè A, Geerts D, Stefan S, Klapproth S, Wagner E, Kobold S, Gabriele Multhoff G.
CAR T cells targeting membrane-bound Hsp70 on tumor cells mimic Hsp70-primed NK cells.
Frontiers in Immunology 2022; 13:883694.
JIF²⁰²¹ 8.8

206. Lücke AC, vom Hemdt A, Wieseler J, Fischer C, Feldmann M, Rothenfusser S, Drexler JF, Kümmerer BM.
High-throughput platform for detection of neutralizing antibodies using flavivirus reporter replicon particles.
Viruses 2022; 4:346.
JIF²⁰²¹ 5.0

206. Arendt K, Ntaliarda G, Armenis V, Kati D, Henning Ch, Giotopoulou G, Pepe M, Klotz L, Lamort A, Hatz R, Kobold S, Schamberger A, Stathopoulos G.
An in vivo inflammatory loop potentiates KRAS blockade.
Biomedicines 2022; 10,592.
JIF²⁰²¹ 6.1

206. Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K, Forster M, Wessels U, Stubenrauch KG, Benz J, Ehler A, Lauer ME, Ringler P, Kobold S, Endres S, Klein Ch, Brinkmann U.
Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies.
Biological Chemistry 2022; 403:495-508.
JIF²⁰²¹ 5.2

205. Scheck MK, Lehmann L, Zaucha M, Schwarzlmueller P, Huber K, Pritsch M, Barba-Spaeth G, Thorn-Seshold O, Krug AB, Endres S, Rothenfusser S, Thorn-Seshold J.
FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D.
PLOS One 2022; 17:e0262149.
JIF²⁰²¹ 3.8

204. Kruger S, Lohneis A, Abendroth A, Berger AW, Ettrich TJ, Waldmann O, Kapp M, Steiber B, Kumbrink J, Reischer A, Haas M, Westphalen CB, Zhang D, Miller-Phillips L, Burger PJ, Kobold S, Werner J, Subklewe M, von Bergwelt-Baildon M, Kunzmann V, Seufferlein T, Siveke JT, Sinn M, Heinemann V, Ormanns S*, Boeck S*.
Prognosis and tumorbiology of pancreatic cancer patients with isolated lung metastases: clinical and translational results from the German multicenter AIO-YMO-PAK-0515 study.
*authors contributed equally
ESMO Open 2022; 7:100388.
JIF²⁰²¹ 6.9

204. Darwich A, Silvestri A, Benmebarek MR, Mouries J, Melacarne A, Cadilha B, Taleb A, Supino D, Obeck H, Sustmann C, Morelli L, Masci G, Losurdo A, Curigliano G, Kobold S, Penna G, Rescigno M.
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by Chitinase 3-like-1.
Journal for Immunotherapy of Cancer 2021; 9:e003224.
JIF²⁰²⁰ 13.8

204. Cadilha B, Benmebarek MR, Dorman K, Oener A, Lorenzini T, Obeck H, Väntinnen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Maerkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S.
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumor.
Science Advances 2021; 7:eabi5781.
JIF²⁰²⁰ 13.1
https://pubmed.ncbi.nlm.nih.gov/34108220/

203. Winheim E, Rinke L, Lutz K, Reischer A, Leutbecher A, Wolfram L, Rausch L, Kranich J, Wratil PR, Huber JE, Baumjohann D, Rothenfusser S, Schubert B, Hilgendorff A, Hellmuth JC, Scherer C, Muenchhoff M, von Bergwelt-Baildon M, Stark K, Straub T, Brocker T, Keppler OT, Subklewe M, Krug AB.
Impaired function and delayed regeneration of dendritic cells in COVID-19.
PLOS Pathogens 2021; 17:e1009742.
JIF²⁰²⁰ 6.2
https://pubmed.ncbi.nlm.nih.gov/34614036/

203. Schneider M, Heeb L, Beffinger M, Pantelyushin S, Linecker M, Roth L, Lehmann K, Ungethüm U, Kobold S.
Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.
Science Translational Medicine 2021; 13:eabc8188.
JIF²⁰²⁰ 16.3
https://www.science.org/doi/10.1126/scitranslmed.abc8188

203. Tokarew N, Gosalvez Suarez J, Nottebrock A, Briukhovetska D, Endres S, Cadilha B, Kobold S.
Flow cytometry detection and quantification of CAR T cells into solid tumors.
Methods in Cell Biology 2021;
JIF²⁰²⁰ 1.4
https://www.sciencedirect.com/science/article/pii/S0091679X21000583?dgcid=author

202. Boehmer D, Formisano S, de Oliveira Mann C, Mueller S, Kluge M, Metzger P, Rohlfs M, Hörth Ch, Kocheise L, Lichtenthaler S, Hopfner KP, Endres S, Rothenfusser S, Friedel C, Duewell P, Schnurr* M, Koenig* L.
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.
Science Immunology 2021; 61, eabe2550.
JIF²⁰²¹ 30.6
https://immunology.sciencemag.org/content/6/61/eabe2550
https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/programmierter-zelltod-von-tumorzellen-durch-synthetische-rna-molekule/3b1205f11defadda

201. Magg* Th, Okano* T, Koenig* L, Boehmer D, Schwartz S, Inoue K, Heimall J, Licciardi F, Ley-Zaporozhan J, Ferdman R, Park E, Calderon B, Dey D, Kanegane H, Cho K, Montin D, Reiter K, Griese M, Albert M, Rohlfs M, Gray P, Walz C, Conn G, Sullivan K, Klein Ch, Morio* T, Hauck* F.
Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency.
Science Immunology 2021; 60, eabf9564.
JIF²⁰²¹ 30.6
https://immunology.sciencemag.org/content/6/60/eabf9564
*contributed equally

201. Di Pilato M*, Kfuri-Rubens R*, Pruessmann J*, Ozga AJ*, Messemaker M, Cadilha B, Sivakumar R, Cianciaruso Ch, Warner RD, Marangoni F, Carrizosa E, Lesch S, Billingsley J, Perez-Ramos D, Zavala F, Rheinbay E, Luster AD, Gerner MY, Kobold S, Pittet MJ, Mempel TR.
CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.
Cell 2021, 184:4512-30.
JIF²⁰²⁰ 41.6
https://www.sciencedirect.com/science/article/abs/pii/S0092867421008564?dgcid=coauthor
*contributed equally

201. Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, Dantes Z, Rataj F, Dorman K, Lutz J, Karches C, Heise C, Kurzay M, Larimer B, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth Ch, Benmebarek MR, Dhoqina D, Gruenmeier R, Seifert M, Oener A, Umut Ö, . . . Rothenfusser S, Duewell P, Koenig L, Schnurr M, Subklewe M, Liss A, Halama N, Reichert M, Mempel T, Endres S, Kobold S.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
Nature Biomedical Engineering 2021; 35:2243-2257.
JIF²⁰²⁰ 20.0
https://www.nature.com/articles/s41551-021-00737-6
https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/neue-strategie-gegen-bauchspeicheldrusenkrebs/f95d2c0d7ad55197

200. Linder A, Bothe V, Linder N, Schwarzlmüller P, Dahlström F, Bartenhagen Ch, Dugas M, Pandey D, Thorn-Seshold J, Boehmer D, König LM, Kobold S, Schnurr M, Rädler J, Spielmann G, Karimzadeh H, Schmidt A, Endres S, Rothenfusser S.
Defective interfering genomes and the full-length viral genome trigger RIG-I after infection with vesicular stomatitis virus in a replication dependent manner.
Frontiers in Immunology 2021; 12:595390.
JIF²⁰²⁰ 6.4
http://journal.frontiersin.org/article/10.3389/fimmu.2021.595390/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Immunology&id=595390

199. Blaeschke F, Stenger D, Apfelbeck A, Cadilha B, Benmebarek MR, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, Willer S, Kaeuferle T, Majzner R, Busch D, Kobold S, Feuchtinger T.
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
Blood Cancer Journal 2021; 11:108.
JIF²⁰²⁰ 8.0

199. Brand I, Gilberg L, Bruger JM, Gari M, Wieser A, Eser TM, Frese J, Ahmed M, Rubio-Acero R, Guggenbuehl Noller JM, Casteletti N, Diekmannshemke J, Thiesbrummel S, Huynh D, Winter S, Fuchs Ch, Hoelscher M, Roider J, Kobold S, Pritsch M, Geldmacher Ch.
Broad T cell targeting of structural proteins after SARS-CoV-2 infection: High throughput assessment of T cell reactivity using an automated interferon gamma release assay.
Frontiers in Immunology 2021; 12:688436.
JIF²⁰²⁰ 6.4

199. Sams L, Kruger S, Heinemann V, Bararia D, Haebe S, Alig S, Haas M, Zhang D, Westphalen CB, Ormanns S, Metzger P, Werner J, Weigert O, von Bergwelt‐Baildon M, Rataj F, Kobold S, Boeck S.
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab‐paclitaxel.
Clinical and Translational Oncology 2021; 23:2394-2401.
JIF²⁰²⁰ 2.8

199. Karaki S, Blanc C, Tran T, Galy-Fauroux I, Mougel A, Dransart E, Anson M, Tanchot C, Paolini L, Gruel N, Gibault L, Le Pimpec-Barthes F, Fabre E, Benhamouda N, Badoual C, Damotte D, Donnadieu E, Kobold S, Mami-Chouaib F, Golub R, Johannes L, Tartour E.
CXCR6-deficiency impairs cancer vaccine efficacy and CD8+resident memory T cell recruitment in head and neck and lung tumors.
Journal for Immunotherapy for Cancer 2021; 9:e001948.
JIF²⁰²⁰ 10.3
https://cancerimmunolres.aacrjournals.org/content/7/2_Supplement/A172

199. Benmebarek MR, Cadilha B, Hermman M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger Ch, Brauchle B, Rohrbacher L, Oener A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein Ch, Subklewe M, Endres S, Hopfner KP, Kobold S.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Leukemia 2021; 35:2243-2257.
JIF²⁰²⁰ 8.7
https://pubmed.ncbi.nlm.nih.gov/33414484/

198. Kuhlmann C, Schenck TL, Tluczynski K, Aszodi A, Metzger P, Giunta R, Wiggenhauser PS.
Experimental approach to nasal septal cartilage regeneration with adipose tissue-derived stem cells and decellularized porcine septal cartilage.
Xenotransplantation 2020; 1-11.
JIF²⁰¹⁹ 3.5
https://pubmed.ncbi.nlm.nih.gov/33350016/

198. Piseddu I, Röhrle N, Knott M, Moder S, Eiber S, Schnell K, Vetter V, Meyer B, Layritz P, Kühnemuth B, Wiedemann G, Grün J, Perleberg C, Rapp M, Endres S, Anz D.
Constitutive expression of CCL22 Is mediated by T cell-derived GM-CSF.
The Journal of Immunology 2020; 205:2056-2065.
JIF²⁰¹⁹ 4.3
https://pubmed.ncbi.nlm.nih.gov/32907996/

197. Segura-Bayona S, Villamor-Paya M, Attolini C, Koenig LM, Sanchiz-Calvo M, Boulton SJ, Stracker TH.
Tousled-like kinases suppress innate immune signaling triggered by alternative lengthening of telomeres.
Cell Reports 2020; 32:107983
JIF²⁰¹⁹ 7.7
https://pubmed.ncbi.nlm.nih.gov/32755577/

197. Boehmer D, Koehler L, Magg T, Metzger P, Rohlfs M, Ahlfeld J, Rack-Hoch A, Reiter K, Albert M, Endres S, Rothenfusser S, Klein Ch, Koenig L, Hauck F.
A novel complete autosomal recessive STAT1 LOF variant causes immunodeficiency with hemophagocytic lymphohistiocytosis-like hyperinflammation.
The Journal of Allergy and Clinical Immunology 2020; 8:3102-3111.
JIF²⁰¹⁹ 10.3
https://pubmed.ncbi.nlm.nih.gov/32603902/

196. Geiger M, Stubenrauch KG, Sam J, Richter W, Jordan G, Eckmann J, Hage C, Gonzalez-Nicolini V,
Freimoser-Grundschober A, Ritter M, Lauer M, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres S, Kobold S, Umaña P, Brünker P, Klein Ch.
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Nature Communications 2020; 11:3196. Featured in Editors‘ Highlights “Translational and clinical research”
JIF²⁰¹⁹ 12.1
https://pubmed.ncbi.nlm.nih.gov/32581215/ 

195. Metzger P, Kirchleitner S, Boehmer D, Hörth Ch, Eisele A, Ormanns S, Gunzer M, Lech M, Lauber K, Endres S, Duewell P, Schnurr M, König L.
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Cancer Immunology, Immunotherapy 2020; 69:2101-2112.
JIF²⁰¹⁹ 4.9
https://pubmed.ncbi.nlm.nih.gov/32448983/

195. Stenger D, Stief T, Kaeuferle T, Willier S, Rataj F, Schober K, Binje V, Lotfi R, Wagner B, Grünewald T, Kobold S, Busch D, Jeremias I, Blaeschka F, Feuchtinger T.
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Blood 2020; 136:1407-1418.
JIF²⁰¹⁹ 10.7
https://pubmed.ncbi.nlm.nih.gov/32483603/

195. Huber J*, Ahlfeld J*, Scheck M, Zaucha M, Witter K, Lehmann L, Karimzadeh H, Pritsch M, Hölscher M, von Sonnenburg F, Dick A, Barba-Spaeth G, Krug A, Rothenfußer S*, Baumjohann D* .
Dynamic changes in circulating T follicular helper cell composition predict neutralizing antibody responses after yellow fever vaccination.
Clinical & Translational Immunology 2020; 9:e1129.
* equally contributed
JIF²⁰¹⁹ 6.5
https://pubmed.ncbi.nlm.nih.gov/32419947/

193. Metzger P, Kirchleitner S, Kluge M, Koenig L, Hoerth Ch, Rambuscheck CA, Boehmer D, Ahlfeld J, Kobold S, Friedel C, Endres S, Schnurr M, Duewell P.
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.
Journal for Immunotherapy of Cancer 2019; 7:288.
JIF²⁰¹⁹ 8.7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836385/

193. Scherm M, Serr I, Zahm A, Schug J, Bellusci S, Manfredini R,Salb V, Gerlach K, Weigmann B, Ziegler AG, Kästner KH, Daniel C.
miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes.
Nature Communications 2019; 10:5697.
JIF²⁰¹⁹ 12.1

193. Scherm M, Serr I, Kästner KH, Daniel C.
The role of T cell miRNAs for regulatory T cell induction in islet autoimmunity.
Molecular Metabolism 2019; 27S:S122-S128.
JIF²⁰¹⁹ 6.5

193. Becker M, Serr I, Salb V, Ott V, Mengel L, Blüher M, Weigmann B, Hauner H, Tschöp M, Daniel C.
Short-term cold exposure supports human Treg induction in vivo.
Molecular Metabolism 2019; 28:73-82.
JIF²⁰¹⁹ 6.5

193. Lorenz G, Moschovaki-Filippidou F, Würf V, Metzger P, Steiger S, Batz F, Carbajo-Lozoya J, Koziel J, Schnurr M, Cohen CD, Schmaderer Ch, Anders HJ, Lindenmeyer M, Lech M*.
IFN regulatory factor 4 controls post-ischemic inflammation and prevents chronic kidney disease.
Frontiers in Immunology 2019; 10:2162.
JIF²⁰¹⁹ 5.1

192. Schewe J, Makeschin MC, Liss I, Mayr D, Zhang J, Khandoga A, Rothenfußer S, Schnurr M, Gerbes AL, Steib CJ.
Ischemic postconditioning (IPostC) protects fibrotic and cirrhotic rat livers after warm ischemia.
Canadian Journal of Gastroenterology and Hepatology 2019; 2019:5683479.
JIF²⁰¹⁹ 2.1

192. Helms M, Jahn-Hofmann K, Gnerlich F, Metz-Weidmann Ch, Braun M, Dietert G, Scherer P, Grandien K, Theilhaber J, Cao H, Wagenaar T, Schnurr M, Endres S, Wiederschain D, Scheidler S, Rothenfusser S, Brunner B, Koenig L.
Utility of the RIG-I agonist triphosphate RNA for melanoma therapy.
Molecular Cancer Therapeutics 2019; 18:2343-2356.
JIF²⁰¹⁹ 5.6
https://www.ncbi.nlm.nih.gov/pubmed/31515294

191. Mountford SA, Ringleb A, Schwaiger R, Mayr D, Kobold S, Dinarello Ch, Bufler P.
Interleukin-37 inhibits colon carcinogenesis during chronic colitis.
Frontiers in Immunology 2019; 10:2632.
JIF²⁰¹⁹ 5.1

191. Brown P, Tan AC, El-Esawi MA, Liehr T, Blanck O, Gladue DP, ...Kobold S, ..., Veys R, Zhou YQ.
Large expert-curated database for benchmarking document similarity detection in biomedical literature search.
Database 2019; doi: 10.1093.
JIF²⁰¹⁹ 2.6

191. Küpper C, Heinrich J, Kamm K, Bücklein V, Rothenfusser S, Straube A.
Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency.
Neurology Neuroimmunology & Neuroinflammation 2019; 6:e628.
JIF²⁰¹⁹ 7.7 

191. Darowski D, Jost Ch, Stubenrauch K, Wessels U, Benz J, Ehler A, Freimoser-Grundschober A, Brünker P, Mössner E, Umana P, Kobold S, Klein Ch.
P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.
Protein Engineering, Design and Selection 2019; 32:207-218.
JIF²⁰¹⁹ 1.9

191. Wiedemann G, Röhrle N, Makeschin MC, Fesseler J, Endres S, Mayer D, Anz D.
Peritumoral CCL1 and CCL2 expressing cells in hepatocellular carcinomas shape the tumor immune infiltrate.
Pathology 2019; 51:586-592.
JIF²⁰¹⁹ 3.8
https://www.ncbi.nlm.nih.gov/pubmed/31445808

190. Karches C, Benmebarek MR, Schmidbauer M, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha B, Lesch S, Heise C, Murr R, vom Berg J, Jastroch M, Lamp D, Ding J, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein Ch, Kobold S.
Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy.
Clinical Cancer Research 2019; 25:5890-5900.
JIF²⁰¹⁹ 10.1
https://www.ncbi.nlm.nih.gov/pubmed/31285373

189. Rapp M, Wintergerst M, Kunz W, Vetter V, Knott M, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian U, Endres S*, Anz D. (*corresponding author)
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
Journal of Experimental Medicine 2019; 116:5514-5522.
JIF²⁰¹⁹ 11.7
https://www.ncbi.nlm.nih.gov/pubmed/3091079  

188. Liu X, Li J, Cadilha B, Markota A, Voigt C, Huang Z, Lin P, Wang D, Juncheng D, Kranz G, Krandick A, Libl D, Zitzelsberger H, Zagorski I, Braselmann H, Pan M, Zhu S, Huang Y, Niedermeyer S, Reichel Ch, Uhl B, Briukhovetska D, Suarez Gosalvez J, Kobold S, Gires O, Wang H.
Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis.
Science Advances 2019; 5:eaav4275.
JIF²⁰¹⁹ 13.1  

188. Eisenmesser EZ, Gottschlich A, Redzic JS, Paukovich N, Nix JC, Azam T, Zhang L, Zhao R, Kieft JS, The E, Meng X, Dinarello CA.
Interleukin-37 monomer is the active form for reducing innate immunity.
Proceedings of the National Academy of Sciences 2019; 116:5514-5522.
JIF²⁰¹⁹ 9.4
https://www.ncbi.nlm.nih.gov/pubmed/30429531

188. Rataj F, Jacobi S, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha B, van Puijenbroek E, Heise C, Duewell P, Endres S, Klein Ch, Kobold S.
High affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
British Journal of Cancer 2019; 120:79-87.
JIF²⁰¹⁹ 5.8
https://www.ncbi.nlm.nih.gov/pubmed/30429531

187. Wiedemann G, Aithal C, Kraechan A, Heise C, Cadilha B, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.
Microphthalmia-associated transcription factor (MITF) regulates immune cell migration into melanoma.
Translational Oncology 2019; 12:350-360.
JIF²⁰¹⁹ 3.6

186. Karsten MM, Enders S, Knabl J, Kirn V, Duewell P, Rack B, Blohmer JU, Mayr D, Dian D.
Biologic meshes and synthetic meshes in cancer patients: a double-edged sword: differences in production of IL-6 and IL-12 caused by acellular dermal matrices in human immune cells.

Archives Gynecology Obstetrics 2018; 297:1265-1270.
JIF²⁰¹⁸ 2.2

186. Kuehnemuth B, Piseddu I, Wiedemann G, Lauseker M, Kuhn Ch, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D.
CCL1 is a major regulatory T cell attracting factor in human breast cancer.
BMC Cancer 2018; 18:1278.

JIF²⁰¹⁸ 2.9

185. Weidenbusch M, Song S, Iwakura T, Shi C, Rodler S, Kobold S, Mulay SR, Honarpisheh MM, Anders HJ.
IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis.
Physiological Reports 2018; 6:e13817.
JIF²⁰¹⁸ 1.3

185. Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood 2018; 32:2484-2494.
JIF²⁰¹⁸ 15.1

185. Rataj F, Kraus F, Chaloupka M, Grassmann S, Heise C, Cadilha B, Duewell P, Endres S, Kobold S.
PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin-lymphoma.

Frontiers in Immunology 2018; 9:1955.

JIF²⁰¹⁸ 4.7
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01955/full

184. Metzger P, Kirchleitner S, König L, Hörth Ch, Kobold S, Endres S, Schnurr M, Duewell P.
Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Science Reports 2018; 8:8810.
JIF²⁰¹⁸ 4.1 

183. Andrade L, Tay R, Pan D, Luoma A, Ito Y, Badrinath S, Tsoucas D, Franz B, May K, Harvey Ch, Kobold S, Pyrdol J, Yoon Ch, Yuan G, Hodi S, Dranoff G, Wucherpfennig K.
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity.
Science 2018; 359:1537-1542.

JIF²⁰¹⁸ 41.1
https://www.ncbi.nlm.nih.gov/pubmed/29599246

183. Makanyengo R, Duewell P, Reichl C, Hörth Ch, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold S, Endres S, Schnurr M, Bauer Ch.
Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gut.
JCI Insight 2018; 8;3(5).

JIF²⁰¹⁸ 6,0

182. Christ A, Günther P, Lauterbach MAR, Duewell P, Biswas D, Pelka K, Scholz CJ, Oosting M, Haendler K, Baßler K, Klee K, Schulte-Schrepping J, Ulas T, Moorlag SJCFM, Kumar V, Park MH, Joosten LAB, Groh LA, Riksen NP, Espevik T, Schlitzer A, Li Y, Fitzgerald ML, Netea MG, Schultze JL, Latz E.
Western diet triggers NLRP3-dependent innate immune reprogramming.
Cell 2018; 172:162-175.
JIF²⁰¹⁸ 31.4
https://www.ncbi.nlm.nih.gov/pubmed/29328911

182. Damby D, Horwell C, Baxter P, Kueppers U, Schnurr M, Dingwell D, Duewell P.

Volcanic ash activates the NLRP3 inflammasome in murine and human macrophages.
Frontiers in Immunology 2017; 8:2000
JIF²⁰¹⁸ 6.4
https://www.ncbi.nlm.nih.gov/pubmed/29403480

182. Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt K, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler W, Schnurr M, Rothenfußer S, Endres S, Kobold S.
Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.
Proceedings of the National Academy of Sciences 2017; 10:1073
JIF 9.6
https://www.ncbi.nlm.nih.gov/pubmed/?term=voigt+c+may+p
* contributed equally to this study

181. Zwicker S, Hattinger E, Bureik D, Batycka-Baran A, Schmidt A, Gerber PA, Rothenfusser S, Gilliet M, Ruzicka T, Wolf R.
Th17 micro-milieu regulates NLPR1-dependent caspase-5 activity in skin autoinflammation.
PLoS One 2017; 12:e0175153
JIF 3.5

181. Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H.
Data on chow, liver tissue and mitochondrial fatty acid compositions as well as mitochondrial proteome changes after feeding mice a western diet for 6-24 weeks.
Data Brief 2017; 15:163-169

181. Ahlfeld J, Filser S, Schmidt F, Wefers AK, Merk DJ, Glaß R, Herms J, Schüller U
Neurogenesis from Sox2 expressing cells in the adult cerebellar cortex.
Scientific Report - Nature 2017; 7:6137
JIF 4.3

181. Freier CP, Kuhn C, Endres S, Mayr D, Freise K, Jeschke U, Anz D.
FOXP3+ cells recruited by CCL22 into breast cancer correlates with less tumor nodal infiltration.
Anticancer Research 2016; 36:3139-45.
JIF 1.9

180. Matheis F, Heppt MV, Graf SA, Düwell P, Kammerbauer C, Aigner A, Besch R, Berking C.
A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma.
Journal of Investigative Dermatology 2016, 136:2475-2484
JIF 6,3

180. Tufman A, Huber RM, Völk S, Aigner F, Edelmann M, Gamarra F, Kiefl R, Kahnert K, Tian F, Boulesteix AL, Endres S, Kobold S.

Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.
BMC Cancer 2016; 16:409.
JIF 3.8

179. Wiedemann G, Jacobi S, Chaloupka M, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S.

A novel TLR7 agonist reverses NK cell anergy and cures lymphoma-bearing mice.
Oncoimmunology 2016; 5:e1189051.

JIF 6.3  

178. Wiedemann G, Knott M, Vetter V, Rapp M, Haubner S, Fesseler J, Kühnemuth B, Layritz P,
Thaler R, Kruger S, Ormanns S, Mayr D, Endres S, Anz D.
Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.
Oncoimmunology 2016; 5:e1175794.
JIF 6.3

177. Hotz C, Treinis M, Mottas I, Rötzer L, Oberson A, Spagnuolo L, Perdicchio M, Spinetti T, Herbst T, Bourquin C.
Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.
Oncoimmunology 2016; 5:e1232219
JIF 7.7

177. Roskopf CC, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS.
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
Oncotarget 2016; 7:22579-89.
JIF 6.6

177. Pritsch M, Ben-Khaled N, Chaloupka M, Kobold S, Berens-Riha N, Peter A, Liegl G, Schubert S, Hölscher M, Löscher T, Wieser A.
Comparison of intranasal outer membrane vesicles with cholera toxin and injected MF59C.1 as adjuvants for malaria transmission blocking antigens AnAPN1 and Pfs48/45.
Journal of Immunology Research 2016; 2016:3576028.
JIF 2.9

177. Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert N, Croasdale R, Klein C,
Scheuer W, Niederfellner G, Auer J, Kobold S, Sustmann C.
TetraMabs: Simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.
Protein Engineering Design and Selection 2016; 29:467-75.
JIF 2.5

176. Heidegger S, Jarosch A, Schmickl M, Endres S, Bourquin C, Hotz C.
Mycoplasma hyorhinis-contaminated cell lines activate primary innate immune cells via a protease-sensitive factor.
PLOS ONE 2015; 10:e0142523.
JIF 3.7

175. Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.

Oncoimmunology 2015; 5:e1105428.
JIF 6.3

174. Lichtenegger F, Kondla I, Krempasky M, Weber A, Herold T, Krupka C, Spiekermann K.
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Cancer Immunology Immunotherapy 2015; 64:1505-15.
JIF 4.0

174. Anz D, Rapp M, Eiber S, Koelzer V, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann G, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C.
Suppression of intratumoral CCL22 by type I interferon inhibits migration of regulatory T cells and blocks cancer progression.
Cancer Research 2015; 75:4483-93.
JIF 9.3

173. Häcker G, Senft D, Weber A, Saathoff F, Berking C, Heppt M, Kammerbauer C, Rothenfusser S, Kellner S, Kurgys Z, Besch R.
In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins.

Cell Death and Disease 2015; 6:e1996.
JIF 5.0

173. Hotz C, Roetzer L, Huber T, Sailer A, Oberson A, Treinies M, Heidegger S, Herbst T, Endres S, Bourquin C.
TLR and RLR signaling are reprogrammed in opposite directions after detection of viral infection.
The Journal of Immunology 2015; 195:4387-95.
JIF 5.4

172. Schnarfell F, Lichtenegger F, Emmerig K, Schlueter M, Neitz J, Draenert R, Hiddemann W, Subklewe M.
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.

Journal of Haematology and Oncology 2015; 8:93.
JIF 4.9

172. Kobold* S, Grassmann* S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#.

Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.
The Journal of the National Cancer Institute 2015; 107.
* contributed equally to this study, # share senior authorship
JIF 15.2
http://www.ncbi.nlm.nih.gov/pubmed/26105028

171. Freier C, Kuhn C, Rapp M, Endres S, Mayr D, Friese K, Anz D, Jeschke U.
Expression of CCL22 and infiltration by regulatory T-cells are increased in the decidua of human miscarriage placentas.
American Journal of Reproductive Immunology 2015; 74:216-27.
JIF 2.7

170. Duewell P, Beller E, Kirchleitner S, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold S, Endres S, Schnurr M.
Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.
OncoImmunology 2015; 4:e1029698.
JIF 6.3

169. Bauer C, Hees C, Sterzik A, Bauernfeind F, Mak´Anyengo R, Duewell P, Lehr HA, Noessner E, Wank R, Trauzold A, Endres S, Dauer M, Schnurr M.

Pro- and anti-apoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells towards gemcitabine and T cell-mediated cytotoxicity.
Journal of Immunotherapy 2015; 38:116-26.
JIF 3.4

168. Kocabey S, Meinl H, MacPherson IS, Cassinelli V, Manetto A, Rothenfusser S, Liedl T, Lichtenegger FS.
Cellular uptake of Tile-assembled DNA nanotubes.
Journal of Nanomaterials 2015; 47-60.
JIF 2.4

167. Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner CG, Klein C, Bourquin C, Endres S.
Selective bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer.

The Journal of the National Cancer Institute 2014; 107:364.
JIF 15.2

166. Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, Stieg MR, Grassmann S, Kobold S, Siveke JT, Endres S, Schnurr M.

RIG-I-like helicases induce immunogenic cell death of pancreatic cancer and sensitize tumors killing by CD8+ T-cells.
Cell Death and Differentiation 2014; 21:1825-37.
JIF 8.4

165. Hermans C, Anz D, Engel J, Kirchner T, Endres S, Mayr D.
Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.
PLOS One 2014; 9:e111757
JIF 2.8  

165. Roskopf CC, Schiller C, Braciak TA, Kobold S, Schubert A, Fey GH, Hopfner KP, Oduncu F.
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell.
Oncotarget 2014; 5:6466-83.
JIF 6.6

165. Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D.
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.

Cancer Immunology Immunotherapy 2014; 63:1151-62.
JIF 3.6

165. Wilson NS, Duewell P, Yang B, Li Y, Marsters S, Koernig S, Latz E, Maraskovsky E, Morelli AB, Schnurr M, Ashkenazi A.
Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant.
The Journal of Immunology 2014; 192:3259-68.
JIF 5.5

165. Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Blood 2014; 123:356-65.
JIF 9.9

165. Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M.
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in an murine pancreatic carcinoma model.
Cancer Immunology Immuntherapy 2014; 63:321-33.
JIF 3.6

164. Kim S, Kaiser V, Beier E, Bechheim M, Guenthner-Biller M, Ablasser A, Berger M, Endres S, Hartmann G, Hornung V.
Self-priming determines high type I IFN production by plasmacytoid dendritic cells.
European Journal of Immunology 2014; 44:807-18.
JIF 5.0

163. Kulkarni P. O*, Hartter I*, Mulay R. S*, Hagemann J, Darisipudi N. M, Kumar S, Romoli S, Thomasova D, Ryu M, Kobold S, Anders HJ.
TLR4-induced IL-22 release accelerates kidney regeneration.
Journal of the American Society of Nephrology 2014; 25:978-89.
JIF 9.0 *diese Autoren leisteten gleichwertigen Beitrag

163. Anz D, Kruger S, Haubner S, Rapp M, Bourquin C, Endres S.
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses.
Diabetes, Obesity and Metabolism 2014; 16:569-72.
JIF 5.2

161. Heidegger S*, Anz D*, Stephan N, Bohn B, Herbst T, Fendler WP, Suhartha N, Sandholzer N, Kobold S, Hotz C, Eisenaecher K, Radtke-Schuller S, Endres S, Bourquin C.
Virus-associated activation of innate immunity induces rapid disruption of Peyer’s patches in mice.
Blood 2013; 122:2591-9.
JIF 9.1 *diese Autoren leisteten gleichwertigen Beitrag

160. Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufmann A, Düwell P, Lindner M, Koch I, Heidegger S, Merk M, Rothenfußer S, Schnurr M, Huber RM, Sauter G, Wilczak W, Endres S.

Interleukin-22 is frequently in lung cancer and may contribute to tumor progression in chemotherapy-resistant disease.

Journal of Thoracic Oncology 2013; 8:1032-1042.
JIF 4.5

159. Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C.

A novel bispecific EGFR/Met antibody blocks tumor promoting phenotypic effects induced by resistance to EGFR inhibition and has potent anti-tumor activity.

Oncogene 2013; 32:5593-601.
JIF 7.4

159. Hohenauer T, Berking C, Schmidt A, Haferkamp S, Senft D, Kammerbauer C, Fraschka S, Graf SA, Irmler M, Beckers J, Flaig M, Aigner A, Höbel S, Hoffmann F, Hermeking H, Rothenfusser S, Endres S, Ruzicka T, Besch R.
The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival.

EMBO Molecular Medicine 2013; 5:919-34.

JIF 7.8

158. Heidegger S, Kirchner SK, Stephan N, Bohn B, Suhartha N, Hotz C, Anz D, Sandholzer N, Stecher B, Rüssmann H, Endres S, Bourquin C.
TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in mice.
Journal of Immunology 2013; 190:5313-20.
JIF 5.5

157. Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willimsky G.
Differently immunogenic cancers in mice induce immature myeloid cells that suppress.
CTL in vitro but not in vivo following transfer.
Blood 2013; 121:1740-8.
JIF 9.1

157. Ellermeier J, Wei J, Düwell P, Hoves S, Stieg M, Adunka T, Nörenberg D, Anders HJ, Mayr D,
Pöck H, Hartmann G, Endres S, Schnurr M.
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Cancer Research 2013; 73:1709-20.
JIF 8.7

155. Merk M, Mitchell R, Endres S, Bucala R.
D-dopachrome tautomerase (D-DT or MIF-2): Doubling the MIF cytokine family.
Cytokine 2012; 59:10-7.
JIF 3.5

154. Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D.
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
Clinical and Developmental Immunology 2012; 2012:134081.
JIF 1.8

154. Vollbrecht T, Stirner R, Tufman A, Roider J, Huber RM, Bogner JR, Lechner A, Bourquin C,
Draenert R. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells.

AIDS 2012; 26:F31-7.
JIF 6.4

154. Bauer C, Duewell P, Lehr HA, Endres S, Schnurr M.

Protective and aggravating effects of Nlrp3 inflammasome activation in IBD Models: influence of genetic and environmental factors.
Digestive Diseases 2012; 1:82-90.
JIF 2.7

153. Wenzel M, Wunderlich M, Besch R, Poeck H, Willms S, Schwantes A, Kremer M, Sutter G, Endres S, Schmidt A, Rothenfusser S.
Cytosolic DNA triggers mitochondrial apoptosis via DNA-damage signalling proteins independently of AIM2 and RNA polymerase III.
Journal of Immunology 2012; 188:394-403.
JIF 5.5

151. Schueller V, Heidegger S, Sandholzer N, Suhartha N, Nickels P, Endres S, Bourquin C, Liedl T.
Cellular immunostimulation by CpG-sequence-coated DNA origami structures.
American Chemical Society ACS Nano 2011; 5:9696-702.
JIF 12.1

150. Kobold S, Isernhagen J, Hübel K, Kilic N, Bogner C, Frickhofen N, Bokemeyer C, Fiedler W.
Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.
Bone Marrow Transplantation 2011; 46:1053-6.
JIF 3.5

150. Lech M, Kantner C, Kulkarni O, Ryu M, Vlasova E, Heesemann J, Anz D, Endres S, Martin J, Koichi S, Kobayashi K, Flavell RA, Anders HJ.
Interleukin-1 receptor-associated kinase-M suppresses systemic lupus erythematosus.
Annals of the Rheumatic Diseases 2011; 70:2207-17.
JIF 9.1

149. Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, Fan J, Lue H, Chen Y, Xiong H, Chagnon F, Bernhagen J, Lolis E, Mor G, Lesur O, Bucala R.
The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF).
Proceedings of the National Academy of Sciences USA 2011; 108:E577-85.
JIF 9.7

149. Anz D, Eiber S, Scholz C, Endres S, Kirchner T, Bourquin C, Mayr D.

In breast cancer a high ratio of tumor-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype.
Histopathology 2011; 59:965-74.
JIF 2.9

148. Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D.

Patients with multiple myeloma develop SOX2-Specific autoantibodies after allogeneic stem cell transplantation.

Clinical and Developmental Immunology 2011; 2011:302145.

JIF 3.1

148. Bourquin C, Hotz C, Noerenberg D, Völkl A, Heidegger S, Storch B, Sandholzer N,
Wurzenberger C, Anz D, Endres S.
Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance.
Cancer Research 2011; 71:5123-33.
JIF 8.7

147. Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Morelli AB, Koernig S, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Journal of Immunology 2011; 187:55-63.
JIF 5.5

146. Bauer C, Dauer M, Saraj S, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Schnurr M, Oduncu F, Emmerich B, Mussack T, Bruns C, Rüttinger D, Conrad C, Jauch KW, Endres S, Eigler A.

Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study.
Cancer Immunology Immunotherapy 2011; 60:1097-107.
JIF 3.6

145. Zoglmeier C, Bauer H, Noerenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C.
CpG blocks immune suppression by myeloid-derived suppressor cells in tumor-bearing mice. (see editorial: Lechner M, Epstein A. A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Canc Res 2011 Feb.)
Clinical Cancer Research 2011; 17:1765-75.
JIF 7.8

144. Anz D, Mueller W, Golic M, Kunz WG, Rapp M, Koelzer VH, Ellermeier J, Ellwart JW, Schnurr M, Bourquin C, Endres S.

CD103 is a hallmark of tumor-infiltrating regulatory T cells.

International Journal of Cancer 2011;129:2417-26.
JIF 6.2

142. Bourquin C, Wurzenberger C, Heidegger S, Fuchs S, Anz D, Weigel S, Sandholzer N, Winter G, Coester C, Endres S.
Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response.
Journal of Immunotherapy 2010; 339:935-44.
JIF 3.5

141. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E.
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Nature 2010; 464:1357-6.

JIF 38.6

141. Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, Wurzenberger C, Denzel A, Kammerer R, Zimmermann R, Endres S.
Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in a SV40 T antigen mouse model.
Journal of Immunology 2010; 185:2580-8.
JIF 5.5

140. Bauer C, Duewell P, Mayer T, Lehr HA, Fitzgerald KA, Tschopp J, Endres S, Latz E, Schnurr M.
Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NALP3 inflammasome.
Gut 2010; 59:1192-9.
JIF 10.7

138. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J.
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin-1β production.
Nature Immunology 2009; 11:63-9.
JIF 26.2

137. Berchthold C, Panthel K, Jellbauer S, Köhn B, Roider E, Partilla M, Heesemann J, Endres S, Bourquin C, Rüssmann H.
Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant salmonella.
Infection and Immunity 2009; 77:5501-5508.
JIF 4.1

136. Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, Anz D, Berger M, Poeck H, Hartmann G, Hornung V, Endres S.
Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through TLR7.
Journal of Immunology 2009; 183:6078-86.
JIF 5.5

135. Berger M, Ablasser A, Kim S, Bekeredjian-Ding I, Giese T, Endres S, Hornung V, Hartmann G.
TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.
Journal of Immunotherapy 2009; 32:262-71.
JIF 3.5

134. Schmidt A, Schwerd T, Hellmuth J, Sheng C, Wenzel M, Hoffmann F, Poeck H, Michallet MC, Besch R, Hopfner KP, Endres S, Rothenfusser S.
5'-triphosphate RNA requires base-paired structures to activate anti-viral signaling via RIG-I.
Proceedings of the National Academy of Sciences USA 2009; 106:12067-72.
JIF 9.7

133. Besch R, Poeck H, Hohenauer T, Senft D, Haecker G, Berking C, Hornung V, Endres S, Ruzicka T, Rothenfusser S, Hartmann G.
Proapoptotic signalling by RIG-I and MDA-5 results in tumorspecific apoptosis independent of type I interferons in melanoma.
Journal of Clinical Investigation 2009; 119:2399-411.
JIF 12.8

132. Ablasser A, Poeck H, Berger M , Schlee M, Kim S, Bourquin C, Goutagny N, Jiang Z, Fitzgerald KA, Anz D, Rothenfusser S , Endres S , Hartmann G, Hornung V.
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes.
Journal of Immunology 2009; 182:6824-33.
JIF 5.5

131. Bekeredjian-Ding I, Schaefer M, Hartmann E, Pies R, Parcina M, Schneider P, Giese T, Endres S, Wollenberg B, Hartmann G.
Tumour-derived prostaglandin E2 and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α.
Immunology 2009; 128:439-450.
JIF 3.7

130. Haasters F, Prall WC, Anz D, Endres S, Mutschler M, Dochenva D, Schieker M.
Morphological and immunological characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing.
Journal of Anatomy 2009; 214:759-767.
JIF 2.4

129. Gross O, Poeck H, Bscheider M, Dostert C,Hannesschlaeger N, Endres S, Tardivel A, Tschopp J, Ruland J.
Syk kinase siganling couples to the Nalp3 inflammasome for anti-fungal host defense.
Nature 2009; 459:433-6.
JIF 38.6

128. Anz D, Thaler R, Stephan N,Waibler Z, Trauscheid MJ, Scholz C,Kalinke U, Barchet W, Endres S, Bourquin C.
Activation of melanoma differentiation-associated gene 5 (MDA5) and Toll-like receptors causes rapid involution of thymus.
Journal of Immunology 2009; 182:6044-50.
JIF 5.5

127. Wurzenberger C, Kölzer HV, Schreiber S, Anz D, Vollmar AM, Schnurr M, Endres S, Bourquin C.
Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo.
Cancer Immunology Immunotherapy 2009; 58:901-13.
JIF 3.6

125. Allam R, Pawar RD, Kulkarni OP, Hornung V, Hartmann G, Segerer S, Akira S, Endres S, Anders HJ.
Viral 5'-triphosphate RNA and non CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses.
European Journal of Immunology 2008; 38:3487-3498.
JIF 5.0

124. Dauer M, Lam V, Arnold H, Junkmann J, Kiefl R, Bauer C, Schnurr M, Endres S, Eigler A.
Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production.
Journal of Immunological Methods 2008; 337:97-105.
JIF 2.2

123. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya S S, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Häcker G, Neuenhahn M, Busch D H, Rothenfusser S , Prinz M, Hornung V, Endres S, Tüting T, Hartmann G.
Therapeutic anti-tumor efficacy of 5´-triphosphate-siRNA depends on simultaneous gene-silencing and immuno-stimulatory activity.
Nature Medicine 2008; 14:1256-63.
JIF 24.3

122. Bourquin C , Anz D, Zwioreck K, Lanz AL, Fuchs S, Weigel S, Wurzenberger C, von der Borch P, Golic M, Winter G, Endres S.
Targeting CpG oligonucleotides to the lymph node by nanoparticels elicits efficient antitumoral immunity.
Journal of Immunology 2008; 1;181:2990-8.
JIF 5.5

121. Bourquin C, Haar M, Anz D, Sandholzer N, Neumaier I, Endres S, Skerra A, Schwab M, Linington C.
DNA vaccination efficiently induces antibodies to Nogo-A and does not exacerbate experimental autoimmune encephalomyelitis.
European Journal of Pharmacology 2008; 588:99-105.
JIF 2.6

120. Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, Coester C.
Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG Oligonucleotides.
Pharmaceutical Research 2008; 25:551-62.
JIF 4.7

118. Bauer C, Bauernfeind F, Sterzik A, Orban M, Schnurr M, Lehr HA, Endres S, Eigler A, Dauer M.
Dendritic cell-based vaccination can be combined with gemcitabine to increase survival in a murine pancreatic carcinoma model.
Gut 2007; 5:1275-82.
JIF 3.0

117. Bauer C, Loher F, Dauer M, Mayer C, Lehr HA, Schönharting M, Hallwachs R, Endres S, Eigler A.
The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA, but not TNF-α expression.
Digestive Diseases and Sciences 2007; 52: 1642-52.
JIF 1.6

116. Bekeredjian-Ding I, Inamura S, Giese T, Moll H, Endres S, Sing A, Zähringer U, Hartmann G.
Staphylococcus aureus triggers T cell-independent B cell proliferation through the engagement of the B cell receptor and Toll-like receptor 2.
Journal of Immunology 2007; 178:2803-12.
JIF 6.7

114. Hartmann E, Graefe H, Hopert A, Pries R, Rothenfusser S, Poeck H, Mack B, Endres S,
Hartmann G, Wollenberg B.

Analysis of plasmacytoid and myeloid dendritic cells in nasal epithelium.
Clinical and Vaccine Immunology 2006; 13:1278-86.
JIF 2.6

113. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G.
5'-triphosphate RNA is the ligand for RIG-I.
Science 2006; 314:994-7.
JIF 30.9

112. Kerkmann M, Lochmann D, Weyermann J, Sarris A, Poeck H, Wagner M, Battiany J, Zimmer A, Endres S, Hartmann G.

Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles.
Oligonucleotides 2006; 16: 313-22.
JIF 3.1

111. Eigenbrod S, Derwand R, Jakl V, Endres S, Eigler A.
Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells.
Immunological Investigations 2006; 35:149-65.
JIF 1.2

110. Dauer M, Schad K, Junkmann J, Herten J, Kiefl R, Schnurr M, Endres S, Eigler A.
IFN-α promotes definitive maturation of dendritic cells generated by short term culture of monocytes with GM-CSF and IL-4.
Journal of Leukocyte Biology 2006; 80:278-86.
JIF 4.3

109. Bekeredjian-Ding I, Roth S I, Gilles S, Giese T, Ablasser A, Hornung V, Endres S, Hartmann G.
T cell-independent TLR-induced IL-12p70 production in primary human monocytes.

Journal of Immunology 2006; 176:7438-46.
JIF 6.7

107. Dauer M, Schad K, Herten J, Junkmann J, Bauer C, Kiefl R, Endres S, Eigler A.
FastDC derived from human monocytes within 48 hours effectively prime tumor antigen-specific cytotoxic cells.
Journal of Immunological Methods 2005; 302:145-55.
JIF 2.5

106. Marschner A, Rothenfusser S, Hornung V, Prell D, Krug A, Kerkmann M, Wellisch D, Poeck H, Greinacher A, Giese T, Endres S, Hartmann G.
CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
European Journal of Immunology 2005; 35:2347-57.
JIF 5.4

105. Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A.
Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.
Journal of Immunotherapy 2005; 28:332-42.
JIF 4.0

104. Renner ED, Pawlita I, Hornung V, Hartl D, Albert M, Jansson A, Endres S, Hartmann G, Belohradsky BH, Rothenfusser S.
No indication for a defect in Toll like receptor signalling in patients with hyper IgE syndrome.
Journal of Clinical Immunology 2005; 25:321-8.
JIF 2.6

103. Bekeredjian-Ding I, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, Hartmann G.
Plasmacytoid dendritic cells control TLR7 sensivity of naive B cells via type I IFN.
Journal of Immunology 2005; 174:4043-50.
JIF 6.7

102. Hartmann G, Marschner A, Renner-Viveros P, Stahl-Henning C, Eisenblätter M, Suh JS, Endres S, Tenner-Racz K, Racz P, Steinmann R, Ignatius R.
CpG oligonucleotides induce strong humoral but only weak CD4+ T cell responses to protein antigens in rhesus macaques in vivo.
Vaccine 2005; 23:3310-7.
JIF 2.8

101. Schlender J, Hornung V, Finke S, Guenthner-Biller M, Marozin S, Brzozka K, Moghim S, Endres S, Hartmann G, Conzelmann KK.
Inhibition of Toll-like-receptor 7 and 9-mediated type I IFN production in human plasmacytoid dendritic cells by respiratory syncytial virus and mesales Virus.
Journal of Virology 2005; 79:5507-15.
JIF 5.2

100. Hornung V, Guenthner-Biller M,Bourquin C, Ablasser A, Schlee M, Uematsu S, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G.
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7.
Nature Medicine 2005; 11:263-70.
JIF 30.6

99. Jahrsdorfer B, Mühlenhoff L, Blackwell S E, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Hartmann G.
B cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
Clinical Cancer Research 2005; 11:1490-9.
JIF 6.5

97. Hornung V, Schlender J, Guenthner-Biller M, Rothenfusser S, Endres S, Hartmann G.
Replication dependent potent IFN-α induction in human plasmacytoid dendritic cells by a single-stranded RNA virus.
Journal of Immunology 2004; 173:5935-43.
JIF 7.3

96. Costa LT, Kerkmann M, Hartmann G, Endres S, Bisch PM, Heckl WM, Thalhammer S.
Structural studies of oligonucleotides containing G-quadruplex motifs using atomic force microscopy.
Biochemical and Biophysical Research Communication 2004; 313:1065-72.
JIF 3.2

95. Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, Tuma E, Giese T, Ellwart JW, Endres S, Hartmann G.

IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.
Journal of Immunology 2004; 172:954-63.
JIF 7.3

94. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, Hornung V, Jahrsdorfer B, Giese T, Endres S, Hartmann G.
Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help.
Blood 2004; 103:3058-64.
JIF 10.1

93. Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, Sarris A, Lubenow N, Speiser D, Endres S, Hartmann G.
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.
Blood 2004; 103:2162-9.
JIF 10.1

91. Obermaier B, Dauer M, Herten J, Schad K, Endres S, Eigler A.
Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes.

Biological Procedures Online 2003; 6:197-203.
JIF 2.0

90. Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschluter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG.
Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model
Cancer Research 2003; 63:8962-7.
JIF 8.4

89. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T, Gires O, Endres S, Hartmann G.
Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.
Cancer Research 2003; 63:6478-87.
JIF 8.4

88. Dauer M, Pohl K, Obermaier B, Meskendahl T, Röbe J, Schnurr M, Endres S, Eigler A.
Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-α-treated monocytes are defective in maturation and T-cell stimulation.
Immunology 2003; 110:38-47.
JIF 2.7

87. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S.
Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells.
European Journal of Immunology 2003; 33:1633-41.
JIF 5.4

86. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G.
Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells.
Journal of Immunology 2003; 170:4465-74.
JIF 7.3

85. Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A.
Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors.
Immunology 2003; 170:4069-76.
JIF 2.7

84. Loher F, Schmall K, Freytag P, Landauer N, Hallwachs R, Bauer C, Siegmund B, Rieder F, Lehr HA, Dauer M, Kapp JF, Endres S, Eigler A.
The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice.
Journal of Pharmacological and Experimental Therapeutics 2003; 305:549-56.
JIF 3.4

82. Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M, Rothenfusser S, Wetzel S, Endres S, Hartmann G.
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases.
Journal of Investigative Dermatology 2002; 119:1096-102.
JIF 5.4

81. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G.
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.
Journal of Immunology 2002; 169:3892-9.
JIF 7.3

80. Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G.
Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
European Journal of Immunology 2002; 32:3235-45.
JIF 5.4

79. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G.
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
Journal of Immunology 2002; 7:34-44.
JIF 7.3

78. Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M,Röbe J, Endres S, Eigler A.
Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Cancer Research 2002; 62:2347-52.
JIF 8.4

77. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G.
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
Journal of Leukocyte Biology 2002; 72:83-92.
JIF 4.3

76. Dauer M, Schulze J, Loher F, Endres S, Eigler A.
Determination of thiopurine S-methyltransferase phenotype using thin-layer chromatography and quantitative scanning.
European Journal of Clinical Pharmacology 2002; 58:41-4.
JIF 1.4

74. Howes N, Lerch MM, Mossner J, Endres S, Deviere J, Verreman G, Lucidi V, Charnley R, Imrie C, Hall R, Olah A, Ihse I, Steenbergan W, O'Donnell M, Greenhalf W, Ellis I, Rutherford S, Mountford R, Whitcombe DC, Neoptolemos JP.
High risk of surgical intervention in hereditary pancreatitis.
British Journal of Surgery 2001; 88:475-476.
JIF 2.7

73. Rothenfusser S, Hornung V, Krug A, Towarowski A, Krieg A, Endres S, Hartmann G.
Distinct CpG oligonucleotide sequences activate human gd T cells via interferon-a/-b.
European Journal of Immunology 2001; 31:3525-34.
JIF 5.4

72. Siegmund B, Rieder F, Lehr H.A, Hartmann G, Dinarello C.A, Endres S, Eigler A.
Neutralization of IL-18 decreases in vivo IFNg synthesis and improves experimental colitis in mice.
American Journal of Physiology 2001; 281:1264-73.
JIF 3.7 

71. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bahls R, Giese T, Engelmann H, Endres S, Krieg A, Hartmann G.
TLR expression reveals CpG ODN as a unique microbial stimulus for plasmacytoid dendritic cells; synergy with CD40L to induce IL-12p70.
European Journal of Immunology 2001; 31:3026-37.
JIF 5.4

70. Siegmund B, Welsch J, Meinhardt G, Emmerich B, Endres S, Eigler A.
Phosphdiesterase type 4 inhibitor suppresses expression of antiapoptotic members of the Bcl-2 family in B-CLL cells and induces Il-10- and caspase-independent apoptosis.
Leukemia 2001; 15:1564-71.
JIF 3.2

69. Hacker U, Erhardt S, Tschöp K, Jelinek T, Endres S.
Influence of IL-1RA gene polymorphism on in vivo synthesis of IL-1RA and IL-1β after live yellow fever vaccination.
Experimental and Clinical Immunology 2001; 125:465-69.
JIF 2.7

68. Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A.
Tumor cell lysate-pulsed human dendritic cells induce a T cell response against pancreatic carcinoma cells: an in vitro model for the assesment of tumor vaccines.
Cancer Research 2001; 61:6445-50.
JIF 8.4

67. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z.
Tumor necrosis factor-a mediates RANK ligand stimulation of osteoclast differentiation by autocrine mechanism.
Journal of Cellular Biochemistry 2001; 83:70-83.
JIF 2.8

66. Krug A, Rothenfusser S, Hornung V, Jahrsdörfer B, Blackwell S, Ballas Z, Endres S, Krieg A, Hartmann G.
A new CpG oligonucleotide sequence induces maximal production of IFN-a in plasmacytoid dendritic cells.
European Journal of Immunology 2001; 31:3026-37.
JIF 5.4

65. Tschoep K, Hartmann G, Eigler A, Krug A, Erhardt S, Adams G, Endres S, Delius M.
Shock waves: a novel method for intracytoplasmic delivery of antisense oligonucleotides.
Journal of Molecular Medicine 2001; 79:306-13.
JIF 3.7

64. Siegmund B, Albrich S, Rieder F, Wolf K, Firestein GS, Boyle D, Lehr HA, Hartmann G, Endres S, Eigler A.
Adenosine kinase inhibitor GP515 improves experimental colitis in mice.
Journal of Pharmacological and Experimental Therapeutics 2001; 296:1-6.
JIF 3.4

62. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg A,

Hartmann G, Endres S.
Enhanced dentritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives cell activation in vitro and therapeutic anti-tumor immune responses in vivo.
Journal of Immunology 2000; 165:6278-86.
JIF 7.3

61. Schnurr M, Then F, Galambos P, Scholz C, Siegmund B, Endres S, Eigler A.
Extracellular ATP and TNF-α synergize in the acivation and maturation of human dentritic cells.
Journal of Immunology 2000; 165:4704-9.
JIF 7.3

60. Eigler A, Matschke V, Hartmann G, Erhardt S, Boyle D, Firestein GS, Endres S.

Suppression of TNF-α production in human mononuclear cells by an adenosine kinase inhibitor.
Journal of Leukocyte Biology 2000; 68:97-103.
JIF 4.3

59. Hartmann G, Tschöp M, Bidlingmaier C, Fischer R, Riepl R, Tschöp K, Hautmann H, Endres S, Toepfer M.

High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein.
Cytokine 2000; 12:246-52.
JIF 2.7

58. Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschöp K, Eigler A, Lehr HA, Endres S.
The specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.

Journal of Pharmacology and Experimental Therapeutics 2000; 292:22-30.
JIF 3.9

55. Sinha B, Eigler A, Baumann KH, Greten TF, Moeller J, Endres S.
Nitric oxide downregulates tumour necrosis factor mRNA in Raw 264.7 cells.
Research in Immunology 1998; 149:139-50.
JIF 1.1

54. Hartmann G, Bidlingmaier M, Jahrsdörfer B, Krug A, Hacker U, Eigler A, Endres S.
Oligonucleotide uptake in leukocytes is dependent on extracellular calcium: A hint for the involvement of adhesion molecules?
Nucleosides and Nucleotides 1998; 17:1767-73.
JIF 1.0

53. Hacker UT, Bidlingmaier C, Gomolka M, Keller E, Eigler A, Hartmann G, Folwaczny C, Fricke H, Albert E, Loeschke K, Endres S.
Inflammatory bowel diesease: no linkage disequilibrium between allelic polymorphisms of interleukin-1β and IL-1 receptor antagonist genes.

European Journal of Clinical Investigation 1998; 28:214-19.
JIF 2.2

52. Siegmund B, Eigler A, Hartmann G, Hacker UT, Endres S.
Adrenaline enhances LPS-induced IL-10 synthesis: evidence for a protein kinase A-mediated pathway.
International Journal of Immunopharmacology 1998; 20:57-69.
JIF 1.0

51. Eigler A, Waller-Fontaine K, Moeller J, Hartmann G, Hacker UT, Endres S.
The hairy cell leukemia cell line Eskol spontaneously synthesizes tumor necrosis factor-a and nitric oxide.
Leukemia Research 1998; 22:501-7.
JIF 1.2

50. Hartmann G, Krug A, Bidlingmaier M, Hacker UT, Eigler A, Albrecht R, Endres S.
Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes.
Journal of Pharmacology and Experimental Therapeutics 1998; 285:920-8.
JIF 3.9

49. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S.
Anti-inflammatory activities of cAMP-elevating agents: enhancement of interleukin-10 synthesis and concurrent suppression of tumor necrosis factor production.
Journal of Leukocyte Biology 1998; 63:1-7.
JIF 4.3

47. Folwaczny C, Fricke H, Endres S, Hartmann G, Spannagl M, Jochum M, Loeschke K.
Anti-inflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: a pilot study.
American Journal of Gastroenterology 1997; 92:911-2.
JIF 3.2

46. Hacker UT, Gomolka M, Keller E, Eigler A, Folwaczny C, Fricke H, Albert E, Loeschke K, Endres S.
Lack of association between a polymorphism in the interleukin-1-receptor-antagonist gene and ulcerative colitis.
Gut 1997; 40:623-7.
JIF 3.0

45. Siegmund B, Eigler A, Sinha B, Moeller J, Hartmann G, Endres S.
Suppression of tumor necrosis factor-a production by interleukin-10 is enhanced by cAMP-elevating agents.
European Journal of Pharmacology 1997; 321:231-9.
JIF 2.3

43. Müller C, Jelinek T, Endres S, Loeschke K.
Schwere protrahierte Cholestase nach Allgemeinanästhesie bei einer Patientin mit Alagille-Syndrom.
Zeitschrift für Gastroenterologie 1996; 34:809-12.
JIF 1.0

42. Hartmann G, Waller-Fontaine K, Eigler A, Moeller J, Krug A, Murphy J, AlbrechtR, Endres S.
Specific suppression of human tumor necrosis factor-a synthesis by antisense oligodeoxynucleotides.
Antisense and Nucleic Acid Drug Development 1996; 6:291-9.
JIF 4.0

41. Milani RV, Mandeep RM, Endres S, Eigler A, Cooper ES, Lavie CJ, Ventura HO.
The clinical relevance of circulating tumor necrosis factor-a in acute decompensated chronic heart failure without cachexia.
Chest 1996; 110:992-5.
JIF 1.8

40. Hartmann G, Krug A,Waller-Fontaine K, Endres S.
Oligodeoxynucleotides enhance LPS-stimulated synthesis of tumor necrosis factor: Dependence on phosphorothioate modification and reversal by heparin.
Molecular Medicine 1996; 2:429-38.
JIF 4.0

39. Greten FT, Moeller J, Feldmeier H, Eigler A, Endres S.
Synthesis of tumour necrosis factor-a in tissue culture of rat coecum: lack of suppression by phosphodiesterase inhibitors.
European Journal of Gastroenterology and Hepatology 1996; 8:679-84.
JIF 0.8

38. Greten FT, Sinha B, Haslberger C, Eigler A, Endres S.
Cicaprost and the specific type IV phosphodiesterase inhibitor rolipram synergize in suppression of tumor necrosis factor-a synthesis.
European Journal of Pharmacology 1996; 299:229-33.
JIF 2.3

37. Endres S, Whitaker RE, Ghorbani R, Meydani SN, Dinarello CA.
Oral aspirin or ibuprofen increase ex vivo cytokine synthesis.
Immunology 1996; 87:264-70.
JIF 2.9

35. Angel JB, Saget BM, Walsh SP, Greten TF, Dinarello CA, Skolnik P, Endres S.
Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
AIDS 1995; 9:1137-44.
JIF 6.0

34. Greten TF, Eigler A, Sinha B, Moeller J, Endres S.
The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-α and nitric oxide.
International Journal of Immunopharmacology 1995; 17:605-10.
JIF 1.0

33. Eigler A, Moeller J, Endres S.
Exogenous and endogenous nitric oxide attenuates tumor necrosis factor synthesis in the murine macorphage cell line RAW 264.7.
Journal of Immunology 1995; 154:4048-54.
JIF 7.3

32. Sinha B, Semmler J, Haen E, Moeller J, Endres S.
Radioimmunoassays for cyclic AMP cross react with phosphodiesterase inhibitors and buffer components.
Journal of Pharmacological and Toxicological Methods 1995; 34:29-36.
JIF 1.1

30. Endres S, Sinha B, Stoll D, Fülle HJ.
Amrinone suppresses synthesis of tumor necrosis factor by mononuclear cells in vitro.
Shock 1994; 1:377-80.
JIF 1.3

28. Eigler A, Sinha B, Endres S.
Nitric oxide-releasing agents enhance cytokine-induced tumor necrosis factor synthesis in human mononuclear cells.
Biochemical and Biophysical Research Communication 1993; 196:494-501.
JIF 3.2

27. Endres S, Meydani SN, Ghorbani R, Schindler R, Dinarello CA.
Dietary n-3 fatty acids suppress interleukin‑2 production and mononuclear cell proliferation.
Journal of Leukocyte Biology 1993; 54:599-603.
JIF 4.3

26. Eisenhut T, Sinha B, Gröttrup-Wolfers E, Semmler J, Siess W, Endres S.
Prostacyclin analogs suppress the synthesis of tumor necrosis factor-a in LPS-stimulated human peripheral blood mononuclear cells.
Immunopharmacology 1993; 26:259-64.
JIF 1.8

25. Semmler J, Wachtel H, Endres S.
The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-a production by human mononuclear cells.
International Journal of Immunopharmacology 1993; 15:409-13.
JIF 1.1

24. Semmler J, Gebert U, Eisenhut T, Moeller J, Schönharting MM, Alléra A, Endres S.
Xanthine derivatives: Comparison between suppression of tumour necrosis factor-a production and inhibition of cAMP phosphodiesterase activity.
Immunology 1993; 78:520-5.
JIF 2.9

21. Nerad JL, Griffiths JK, van der Meer JWM, Endres S, Poutsiaka DD, Keusch GT, Bennish M, Salam MA, Dinarello CA, Cannon JG.

Interleukin-1β (IL-1β), IL-1 receptor antagonist, and TNFa production in whole blood.
Journal of Leukocyte Biology 1992; 52:200-5.
JIF 3.6

19. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA, Gorbach SL.
Oral n-3 fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison in young and older women.
Journal of Nutrition 1991; 121:547-55.
JIF 1.9

17. Munoz C, Endres S, van der Meer JWM, Schlesinger L, Arevalo M, Dinarello CA.
Interleukin-1β in human collostrum.
Research in Immunology 1990; 141:505-513.
JIF 1.3

16. Park MM, Hornback NB, Endres S, Dinarello CA.
The effect of whole body hyperthermia on the immune cell activity of cancer patients.
Lymphokine Research 1990; 9:213-23.
JIF 2.6

15. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der MeerJWM, Endres S, Lonneman G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Burke JF, Dinarello CA.
Circulating interleukin‑1 in septic shock and experimental endotoxin fever.
Journal of Infectious Diseases 1990; 161:79-84.
JIF 4.9

13. Endres S, Cannon JG, Ghorbani R, Dempsey RA, Sisson SD, Lonnemann G, vanderMeerJWM, Wolff SM, Dinarello CA.
In vitro production of IL‑1β, IL-1α, TNF αnd IL‑2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation.
European Journal of Immunology 1989; 19:2327-33.
JIF 6.0

12. Lonnemann G, Endres S, van der Meer JWM, Cannon JG, Koch KM, Dinarello CA.
Differences in the synthesis and kinetics of release of interleukin‑1α, interleukin‑1β and tumor necrosis factor from human mononuclear cells.
European Journal of Immunology 1989; 19:1531-6.
JIF 6.0

10. Cannon JG, van der Meer JWM, Kwiatkowski D, Endres S, Lonnemann G, Burke JF, Dinarello CA.
Interleukin-1β in human plasma: Optimization of blood collection, plasma extraction and radioimmunoassay methods.
Lymphokine Research 1988; 7:457‑67.
JIF 2.6

9. Okusawa S, Yancey KB, van der Meer JWM, Endres S, Lonnemann L, Hefter K, Frank MM, Burke JF, Dinarello CA, Gelfand JA.
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro: Comparison with secretion of interleukin-1β and interleukin-1α.
Journal of Experimental Medicine 1988; 168:443‑9.
JIF 15.0

8. Endres S, Ghorbani R, Lonnemann G, van der Meer JWM, Dinarello CA.
Measurement of immunoreactive interleukin-1β from human mononuclear cells: optimization of recovery, intrasubject consistency and comparison with interleukin-1α and tumor necrosis factor.
Clinical Immunology and Immunopathology 1988; 49:424‑38.
JIF 2.1

7. Lonnemann G, Endres S, van der Meer JWM, Cannon JG, Dinarello CA.
A radioimmunoassay for human interleukin‑1α: Measurement of IL-1α produced in vitro by human blood mononuclear cells stimulated with endotoxin.
Lymphokine Research 1988; 7:75‑85.
JIF 2.6

6. Boswell JM, Yui MA, Endres S, Burt DW, Kelley VE.
Novel and enhanced interleukin‑1 gene expression in autoimmune mice with lupus.
Journal of Immunology 1988; 141:118‑24.
JIF 7.4

5. Armanini D, Endres S, Kuhnle U, Weber PC.
Parallel determination of mineralocorticoid and glucocorticoid receptors in T‑ and B‑lymphocytes of human spleen.
Acta Endocrinologica 1988; 118:479‑82.
JIF 2.2

3. Okusawa S, Dinarello CA, Yancey KB, Endres S, Lawley TJ, Frank MM, Burke JF, Gelfand JA.
C5a induction of human interleukin-1. Synergistic effect with endotoxin or interferon‑γ.
Journal of Immunology 1987; 139: 2635‑40.
JIF 7.4

1. Endres S.
Antigenexpression auf aktivierten T-Lymphozyten.
Dissertation, LMU München 1983;

72. Andreu-Sanz D, Kobold S.
Role and promises of different T helper cell subsets in adoptive cell therapy.
Molecular Cancer Biology 2022
JIF 6.6

72. Kandra P, Nandigama R, Eul B, Huber M, Kobold S, Seeger W, Grimminger F, Savai R.
Utility and drawbacks of chimeric antigen receptor T Cell (CAR-T) therapy in lung cancer.
Frontiers in Immunology 2022
JIF 8.8

https://pubmed.ncbi.nlm.nih.gov/35720364/

72. Dalloul I, Strzalkowski T, von Bergwelt-Baildon M, Nüssler V, Zielinski Ch, Kobold S.
9th Immunotherapy of cancer conference (ITOC): a meeting report.
Human Vaccines & Immunotherapeutics 2022
JIF 4.5

72. Drude N, Martinez-Gamboa L, Danzinger M, Collazo A, Kniffert S, Wiebach J, Nilsonne G, Konietschke F, Piper SK, Pawel S, Micheloud Ch, Held L, Frommlet F, Segelcke D, Pogatzki‐Zahn, EM, Voelkl B, Friede T, Brunner E, Dempfle A, Haller B, Jung MJ, Riecken LB, Kuhn HG, Tenbusch M, Serna Higuita LM, Remarque E, Grüninger‐Egli SL, Manske K, Kobold S, Rivalan M, Wedekind L, Wilcke J, Boulesteix AL, Meinhardt M, Spanagel R, Hettmer S, von Lüttichau I, Regina C, Dirnagl U, Toelch U.
Planning preclinical confirmatory multicenter trials to strengthen translation from basic to clinical research.
Translational Medicine Communications 2022, in press.
JIF 8.4

72. Michaelides S, Obeck H, Kechur D, Endres S, Kobold S.
Migratory engineering of T cells for cancer therapy.
Vaccines 2022, in press.
JIF 5.0

71. Tartour E, Mabrouk N, Tran T, Pourmir I, Gruel N, Granier C, Pineau J, Gey A, Kobold S, Fabre E.
CXCR6 expressing T cells: functions and role in the control of tumors.
Frontiers in Immunology 2022, 13:1022136.
JIF 8.8

71. Huynh D, Winter P, Märkl F, Endres S, Kobold S.
Beyond direct killing – novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.
Seminars in Immunopathology 2022; in press.
JIF 11.8

70. Märkl F, Huynh D, Endres S, Kobold S.
Utilizing chemokines in cancer immunotherapy.
Trends in Cancer 2022; 8:670-682.
JIF 14.2

69. Dorman K, Heinemann V, Kobold S, von Bergwelt-Baildon M, Böck S.
Novel systemic treatment approaches for metastatic pancreatic cancer.
Expert Opinion On Investigational Drugs 2022; 31:249-262.
JIF 6.2

68. Umut Ö, Gottschlich A, Endres S, Kobold S.
CAR T cell therapy in solid tumors: a short review.
Magazine of European Medical Oncology 2021; 14:143-149.
JIF 1.0

67. Dezfouli A, Yazdi M, Pockley A, Khosravi M, Kobold S, Wagner E, Multhoff G.
NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development.
Cells 2021; 10:3390.
JIF 6.7

67. Briukhovetska D, Doerr J, Endres S, Libby P, Dinarello Ch, Kobold S.
Interleukins in cancer: from biology to therapy.
Nature Reviews Cancer 2021; 3. Juni 2021
JIF 53.0
https://www.nature.com/articles/s41568-021-00363-z
https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/mit-interleukinen-gegen-den-krebs/94565a179b3a2184

66. Schwerdtfeger M, Desiderio V, Kobold S, Regad T, Zappavigna S, Caraglia M.
Long non-coding RNAs in cancer stem cells.
Translational Oncology 2021; 16:218-233.
JIF 4.1

66. Schwerdtfeger M, Benmebarek MR, Endres S, Subklewe M, Desiderio V, Kobold S.
Chimeric antigen receptor–modified T cells and T cell–engaging bispecific antibodies: different tools for the same job.
Current Hematologic Malignancy Reports 2021

JIF 2.5
https://doi.org/10.1007/s11899-021-00628-2

65. Kobold S.
An in sitro assay to predict primary resistance to PD-1 blockade.
Trends in Molecular Medicine 2021; 27:297-298.
JIF 11.1
https://www.sciencedirect.com/science/article/pii/S147149142100037X?dgcid=author

65. Gottschlich A, Endres S, Kobold S.
Therapeutic strategies for targeting IL-1 in cancer.
Cancers 2021; 13:477.
JIF 6.1
https://www.mdpi.com/2072-6694/13/3/477/pdf

64. Koenig L, Boehmer D, Metzger P, Schnurr M, Endres S, Rothenfusser S.
Blocking inflammation on the way: rationale for CXCR2 antagonists for the treatment of COVID-19.
Journal of Experimental Medicine 2020; 217:e20201342.
JIF 10.9 

62. Lesch S, Benmebarek MR, Cadilha B, Stoiber S, Subklewe M, Endres S, Kobold S.
Determinants of response and resistance to CAR T cell therapy.
Seminars in Cancer Biology 2019
JIF 9.7 

61. Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S.
6th Immunotherapy of cancer conference (ITOC): advances and perspectives, a meeting report.
Journal for ImmunoTherapy of Cancer 2019
JIF 8.7

61. Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S.
6th Immunotherapy of cancer conference (ITOC): advances and perspectives, a meeting report.
Journal for ImmunoTherapy of Cancer 2019
JIF 8.7

61. Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K.
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Radiation Oncology 2019; 14:141.
JIF 2.9 

61. Kruger S, Ilmer M, Kobold S, Cadilha B, Endres S, Ormanns S, Schuebbe G, Renz W, D´Haese J, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.
Advances in cancer immunotherapy 2019 – latest trends.
Journal of Experimental and Clinical Research 2019; 38:268.
JIF 6.2

60. Stoiber S, Cadilha B, Benmebarek MR, Lesch S, Endres S, Kobold S.
Limitations in the design of chimeric antigen receptors for cancer therapy.
Cells 2019; 8:E472:1-26
JIF 7.6

59. Darowski D, Kobold S, Jost C, Klein C.

Combining the best of two worlds: Highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Monoclonal Antibodies 2019; 20:1-11
JIF 5.2
https://doi.org/10.1080/19420862.2019.1596511

59. Benmebarek MR, Karches C, Cadilha B, Lesch S, Endres S, Kobold S*.
Killing mechanisms of chimeric antigen receptor (CAR) T cells.
International Journal of Molecular Sciences 2019; 20(6)
JIF 3.7
https://www.ncbi.nlm.nih.gov/pubmed/?term=Benmebarek+MR

58. Kobold S.
Innate and adaptive immunity combined for cancer treatment. (comment)
Proceedings of the National Academy of Sciences USA 2019, 116:1087-1088
JIF 9.5

58. Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S.
Teaching an old dog new tricks: next generation CAR T cells.
British Journal of Cancer 2019; 120:26-37
JIF 6.2

57. Duewell P, Endres S, Kobold S.
Innate immune stimulation in cancer therapy.
Hematology/Oncology Clinics of North America 2018
JIF 3.1

55. Kobold S, Pantelyushin S, Rataj F, vom Berg J.
Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy.
Frontiers Oncology 2018; 9:1955
JIF 2.0

55. Kobold S, Krackhardt A, Schlösser H, Wolf D.
Immuno-Oncology: A Brief Overview
Deutsche Medizinische Wochenschrift 2018, 143:1006-1013.
JIF 0.6

54. Markota A, Endres S, Kobold S.
Targeting interleukin-22 for cancer therapy.
Human Vaccines & Immunotherapeutics 2018; 14:2012-2015
JIF 2.2

53. Rataj F, Endres S, Kobold S.
When the inhibitor is turned into stimulator: novel aspects in T cell engineering.
Translational Cancer Research 2018
JIF 1.8

51. Kobold S.
Komplexe Biosimilars in der Onkologie. Rituximab, Trastuzumab & co.
TZM News 2017; Ausgabe 4

50. Bauer C, Kuehnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M.
revailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Cancer Letters 2016
JIF 6,0
http://dx.doi.org/10.1016/j.canlet.2016.02.057

49. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Immunotherapie von Tumoren. Aktivierte T-Zellen als gemeinsame Endstrecke neu zugelassener Therapien.
Deutsches Ärzteblatt International 2015; 112:809-15
JIF 3,6
http://www.aerzteblatt.de/treffer?mode=x&wo=16&typ=16&aid=173073&s=Kobold

Immunotherapy in tumors. Activated T cells as a new treatment modality.
Deutsches Ärzteblatt International 2015; 112:809-15
JIF 3,6
http://www.ncbi.nlm.nih.gov/pubmed/26667979

44. Endres S, Meuer S, Scriba PC.
Klinische Immunintervention: aktuelle und künftige Ansätze
Arzneimittelforschung 2012; Volume 62.

43. Hotz C, Bourquin C.
Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything.
Oncoimmunology 2012; 1:227-228.

41. Bourquin C, Voelkl A, Endres S.
Toll-like receptor-7 ligands for the tumor therapy.
Arzneimittel-Forschung Drug Research 2006; 16

38. Dugas M, Weinzierl S, Pecar A, Endres S, Hasford J.
Design and implementation of a common drug information database for a university hospital.
Pharmacy World Science 2003; 25:156-161

37. Endres S, Hartmann G.
Therapeutische Oligonukleotide.
Deutsches Ärzteblatt 2003; 47:2577-82

36. Rothenfusser S, Tuma E, Wagner M, Endres S, Hartmann G.
Recent advances in immunostimulatory CpG-oligonucleotides.
Current Opinions in Microbiology 2003; 5

35. Eigler A, Eigenbrod S, Endres S.
Medikamentös induzierte Pankreatitis.
Deutsche Medizinische Wochenschrift 2003; 128:1-4

33. Rothenfusser S, Tuma E, Endres S, Hartmann G.

Plamacytoid dendritic cells: The key to CpG.
Human Immunology 2002; 63:1111-9

31. Endres S, Buchardi C, Angstwurm M.
Diagnosespektrum in einer internistischen Notaufnahme.
Der Internist 2001; 42:1462-4

30. Kirchgeorg M, Endres S.
Patienten suchen und finden Gesundheitsinformationen im Internet.
Hessisches Ärzteblatt 2001; 9:437-41

29. Eigler A, Loher F, Endres S.
Suppression der Synthese des Tumornekrosefaktors.
Der Internist 2001; 1:28-34

26. Schulze J, Endres S.
Genotyp, Phänotyp und unerwünschte Arzneimittelreaktionen.
Arzneimitteltherapie 1999; 17:196-200

23. Hartmann G, Bidlingmaier M, Eigler A, Hacker UT, Endres S.
Cytokines as targets for therapeutic oligonucleotides.
Cytokines, Cellular and Molecular Therapy 1997; 3:247-56

22. Folwaczny C, Endres S..
Fischöl zur Rezidivprophylaxe bei M. Crohn?.
Zeitschrift für Gastroenterologie 1997; 35:651-3

21. Eigler A, Endres S.
Therapie mit Anti-TNF-αntikörper bei Patienten mit Morbus Crohn.
Zeitschrift für Gastroenterologie 1997; 35:899-901

20. Endres S, Eigler A.
Hemmung der NO-Synthase im septischen Schock.
Der Internist 1997; 38:466-9

19. Hartmann G, Krug A, Bidlingmaier M, Eigler A, Endres S.
Antisense strategies for inhibition of tumor necrosis factor-a synthesis.
Nucleosides and Nucleotides 1997; 629-34

17. Drenth JPH, Endres S, Belohradsky BH, van der Meer JWM.

Das Hyper-IgD-Syndrom.
Deutsche Medizinische Wochenschrift 1996; 121:1299-1300

15. Endres S, Sinha B, Eisenhut T.
n-3 Polyunsaturated fatty acids in the regulation of human cytokine synthesis.
Biochemical Society Transactions 1995; 23:277-81

14. Endres S, Sinha B, Eigler A.
Tumor-Nekrose-Faktor: Therapeutische Strategien zu Synthesehemmung und Antagonismus.
Deutsches Ärzteblatt 1995; 92:2185-8

11. Endres S.
Messengers and mediators: the interaction between lipids, eicosanoids and cytokines.
The American Journal of Clinical Nutrition 1993; 57:789-800

10. Markewitz A, Faist E, Weinhold C, Lang S, Endres S, Hültner L, Reichart B.
Alterations of cell-mediated immune response following cardiac surgery.
European Journal of Cardio-thoracic Surgery 1993; 105:15-24

5. Endres S, Hohnloser J.
Therapeutischer Einsatz von Zytokinen.
Münchner Medizinische Wochenschrift 1989; 131:507-9

1. Endres S.
Praktikum der Inneren Medizin in den USA.
Deutsche Medizinische Wochenschrift 1983; 108:1530-3

3. Oener A, Kobold S.
Transwell migration assay to interrogate human CAR-T cell chemotaxis.
STAR Protocols 2022, 3:101708, JIF 1,3

2. Dauer M, Schad K, Herten J, Endres S, Eigler A.
Author reply to: Dauer M et al. Mature dendritic cells derived from human monocytes within 48 hours: a strategy mimicking dendritic cell differentiation from blood precursors in vivo. Journal of Immunology 2003; 170:4069
Journal of Immunology 2004; 172:3-4

1. Hartmann G, Bidlingmaier M, Jahrsdörfer B, Endres S.
Playground of oligonucleotides: extrapolation from in vitro to in vivo?
Nature Medicine 1997; 3:3

1. Endres S.
   n-3 Fettsäuren und zyklische Nukleotide in der Regulation der Synthese von Interleukin-1 und Tumor-Nekrose-Faktor.
   Habilitationsschrift, LMU München 1992;
2. De Caterina R, Endres S, Kristensen SD, Schmidt EB, editors.
   n-3 Fatty Acids and Vascular Disease.
   Springer-Verlag, Berlin - Heidelberg 1993;
3. Scriba PC, Endres S (Heftherausgeber)
   Klinische Forschergruppen in Deutschland.
   Der Internist 1995; 36(4)
4. Kristensen SD, Schmidt EB, De Caterina R, Endres S, editors.
   Preventive Strategies in Vascular Disease: Focus on n-3 Fatty Acids.
   Springer-Verlag, Berlin - Heidelberg 1995;
5. Scriba PC, Endres S (Heftherausgeber).
   Klinische Pharmakologie: Therapie mit und gegen NO.
   Der Internist 1997; 38(5)
6. Hartmann G, Endres S, editors.
   Manual of Antisense Methodology.
   Kluwer Academic Publishers, Boston 1999;
7. Werdan K., Endres S (Heftherausgeber).
   Zytokine und (Anti-)Zytokintherapie.
   Der Internist 2001; 42(1)
8. Scriba PC, Endres S (Wissenschaftliche Leitung).
   Perspektiven der gastroenterologischen Pharmakotherapie
   Arzneimittel-Forschung Drug Research 2002; 52(12)
9. Endres S, Scriba PC (Heftherausgeber).
   Pharmakotherapie in der Gastroenterologie
   Deutsche Medizinische Wochenschrift 2003; 8
10. Endres S (Herausgeber).
    Facharztprüfung Innere Medizin in Fällen, Fragen und Antworten
    Urban & Fischer 2003;
11. Ruß A, Endres S, Hoffmann C (Herausgeber).
    Arzneimittel manual.
    Börm Bruckmeier Verlag, Grünwald 2005;
12. Hartmann G, Endres S (Heftherausgeber).
    Toll-like receptor-based drug development.
    Arzneimittel-Forschung Drug Research 2006;
13. Schmitz G, Endres S, GötteD (Herausgeber).
    Biomarker: Bedeutung für medizinischen Fortschritt und Nutzenbewertung
    Schattauer Verlag, Stuttgart, 2008; 

1. Endres S, Ghorbani R, Cannon JG, Lonnemann G, van der Meer JWM, Wolff SM, Dinarello CA.
   Humans taking dietary omega-3 fatty acids have decreased in vitro production of interleukin-1. In: Powanda MC, et al., editors.
   Monokines and Other Non‑Lymphocytic Cytokine
   Alan R. Liss, New York 1988; 153-8
2. Cannon JG, van der Meer JWM, Endres S, Lonnemann G, DinarelloCA.
   Interleukin‑1 in human blood: Chloroform extraction and radioimmunoassay. In: Powanda MC, et al., editors.
   Monokines and Other Non‑Lymphocytic Cytokine
   Alan R. Liss, New York 1988; 373‑6
3. Dinarello CA, Endres S.
   Interleukin-1. In: Groopman JE, et al., editors.
   Mechanisms of Action and Therapeutic Applications of Biologicals in Cancer and Immune Deficiency Disorders
   Alan R. Liss, New York 1989; 201-18
4. Endres S, Dinarello CA.
   Interleukin‑1 and tumor necrosis factor - mediators of the acute phase response and possible modes for their manipulation. In: Zor U, et al., editors.
   Leukotrienes and Prostanoids in Health and Disease. New Trends in Lipid Mediator Research
   Karger, Basel 1989; (3)114-8
5. Shapiro AC, Meydani SN, Meydani M, Morrow F, Blumberg J, Endres S, Dinarello CA.
   The effect of fish oil supplementation on plasma alpha‑tocopherol and retinol levels. In: Chandra RK, editor.
   Health Effects of Fish and Fish Oils
   ARTS Biomedical Publishers, St. John's, Newfoundland 1989; 537-46
6. Endres S, Meydani SN, Ghorbani R, Schindler R, Dempsey R, Dinarello CA.
   Interleukin-2 production is suppressed by dietary n-3 fatty acids but enhanced by oral aspirin. In: Dinarello CA, et al., editors.
   Physiological and Pathophysiological Effects of Cytokines
   Alan R. Liss, New York 1990; 281-6
7. Nerad JL, Griffiths JK, van der Meer JWM, Endres S, Keusch GT, Bennish M, Dinarello CA, Cannon JG.
   A simple rapid method for studying cytokine production by endotoxin-stimulated leukocytes. In: Dinarello CA, et al., editors.
   Physiological and Pathophysiological Effects of Cytokines
   Alan R. Liss, New York 1990; 19-24
8. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA, Gorbach SL.
   Effect of oral n-3 fatty acid supplementation on the immune response of young and older women. In: Samuelsson B, et al., editors.
   Advances in Prostaglandin, Thromboxane, and Leukotriene Research
   Raven Press, New York 1990; (21)245-8
9. Endres S, Meydani SN, Dinarello CA.
   Effects of w-3 fatty acid supplements on ex vivo synthesis of cytokines in human volunteers. Comparison with oral aspirin and ibuprofen. In: Simopoulos AP, et al., editors.
   World Rev Nutr Diet
   Karger, Basel 1991; (66)401-6
10. Endres S, Kaminski W, von Schacky C.
    n-3 Fatty acids and the regulation of growth factors and cytokines. In: Frölich JC, von Schacky C, editors.
    Clinical Pharmacology
    Zuckschwerdt, München 1992; (5)98-103
11. Endres S.
    Cytokines and their modulation by n-3 fatty acids with regard to atherogenesis. In: De Caterina R, Kristensen SD, Schmidt EB, editors.
    Fish Oil and Vascular Disease
    Springer-Verlag, Berlin 1992; 59-64
12. Endres S, Meydani SN, Dinarello CA.
    Manipulation of cytokine synthesis through dietary lipids. In: Faist E, et al., editors.
    Proceedings of the Second International Congress on the Immune Consequences of Trauma, Shock and Sepsis
    Springer-Verlag, Berlin 1993; 1013-6
13. Endres S, Fülle HJ, Sinha B, Stoll D, Gerzer R.
    Regulation of cytokine synthesis through cyclic nucleotides. In: Faist E, et al., editors.
    Proceedings of the Second International Congress on the Immune Consequences of Trauma, Shock and Sepsis
    Springer-Verlag, Berlin 1993; 609-12
14. Endres S, Eisenhut T, Sinha B.
    n-3 fatty acids and cytokines. In: De Caterina R, Endres S, Kristensen SD, Schmidt EB, editors.
    n-3 Fatty Acids and Vascular Disease
    Springer-Verlag, Berlin - Heidelberg 1993; 31-8
15. Endres S, Sinha B, Eisenhut T.
    w3 fatty acids in the regulation of cytokine synthesis. In: Galli C, Simoupolous AP, Tremoli E, editors.
    Effects of Fatty Acids and Lipids in Health and Disease. World Rev Nutr Diet
    Karger-Verlag, Basel 1994; (76)143-5
16. Endres S, Eisenhut T, Sinha B.
    Omega-3 fatty acids in the regulation of cytokine synthesis. In: Pownall HJ, Spector AA, Conference Cochairs.
    Proceedings from the Scientific Conference on Omega-3 Fatty Acids in Nutrition, Vascular Biology, and Medicine
    American Heart Association 1995; 146-151
17. Endres S, Gröttrup-Wolfers E, Lorenz R, Loeschke K.
    n-3 Fatty acids in inflammatory bowel disease. In: Kristensen SD, Schmidt EB, De Caterina R, Endres S, editors.
    n-3 Fatty Acids: Prevention and Treatment in Vascular Disease
    Springer-Verlag, Berlin - Heidelberg 1995; 181-8
18. Endres S, Eigler A, Hartmann G.
    n-3 Polyunsaturated fatty acids and human cytokine synthese. In: Yehuda S, Mostofsky DI, editors.
    n-3 Fatty Acids: Biochemistry and Behavior
    Human Press Inc., Totowa, NJ, USA 1999; 609-18f
19. Endres S
    Gastroenterologie. In: Endres S, editor.
    Facharztprüfung Innere Medizin.
    Urban & Fischer-Elsevier, München 2003; 137-219
20. Bourquin C, Anz D, Rothenfußer S, Endres S.
    Toll-like-Rezeptoren als neue Marker und Targets der Pharmakotherapie: Schmitz G, Endres S, Götte D, editors.
    Biomarker: Bedeutung für medizinischen Fortschritt und Nutzenbewertung.
    Schattauer, Stuttgart, New York, 2008; 75-86
21. Endres S, Anz D, Bourquin C.
    Biomarker: Anwendung in der Praxis-Beispiel Gastroenterologie. In: Schmitz G, Endres S, Götte D, editors.
    Biomarker: Bedeutung für medizinischen Fortschritt und Nutzenbewertung.
    Schattauer, Stuttgart, New York, 2008; 115-118
22. Endres S, Kobold S.
    Budenosid: Pharmakologische Grundlagen. In: Miehlke S, Madisch A, editors.
    Topische Steroide in der Gastroenterologie.
    UNI-MED Verlag AG, Bremen, London, Boston, 2013; 12-15

92. S. Endres „Toll-like-receptor 7 agonist and RIG-I-ligands for tumorimmunotherapy".
ITOC-1-Konferenz (Immunotherapy of cancer) Klinikum rechts der Isar, 12. bis 14. März 2014

90. S. Endres "Strategieworkshop Spitzencluster m4".
Posiumsdiskussion "Vernetzung des Spitzenclusters in München und außerhalb der Region" MPI für Biochemie, Martinsried, 15. Februar 2011

89. S. Endres "Translational approach to Research at the LMU".
Interim Evaluation, HelMA "Mental Health in an Ageing Society" Helmholtz Zentrum München, 9. Februar 2011

87. S. Endres "Immunostimulatory RNA Oligonucleotides".
CIPS-M-Wildbad Kreuth-Konferenz Epigenetik und Protein-Nukleinsäure-Interaktion, Wildbad Kreuth, 27. bis 29. September 2010

86. S. Endres "Activating NK cells and inhibiting tregs by RNA oligonucleotides".
8th World Congress on Trauma, Shock, Inflammation and Sepsis - TSIS 2010, München, 9. bis 13. März 2010

85. S. Endres "Therapie und Prävention: Pro-Inflammatorisch - Induktion eines zytotoxischen Milieus".
29. Deutscher Krebskongress, Stukturen verändern, Heilung verbessern, Berlin, 24. bis 27. Februar 2010

83. S. Endres "Anti-tumor activity of immunostimulatory RNA oligonucleotide".
CIPS-M-Kloster Irsee-Konferenz, Epigenetik und Protein-Nukleinsäure-Interaktionen, Kloster Irsee, 11. bis 13. Oktober 2009

2. S. Endres "Effects of dietary omega‑3 fatty acids on the in vitro production of human interleukin‑1."
International Workshop on Monokines and Other Non-Lymphocytic Cytokines, Hilton Head Island, South Carolina, 6. bis 10. Dez. 1987

1. S. Endres "Use of a highly sensitive radioimmunoassay for measuring intraindividual variation of human monocyte interleukin‑1b production."
International Conference on Tumor Necrosis Factor and Related Cytokines, Heidelberg, 14. bis 18. Sept. 1987